Loading
AOP Health
AOP Health is a Vienna rare-disease company that brought ropeginterferon alfa-2b (Besremi) to the European market for polycythaemia vera and runs trials in myeloproliferative neoplasms and other rare conditions.
Also called: AOP Orphan Pharmaceuticals AGAOP OrphanAOP Orphan Pharmaceuticals
Overview
AOP Health (formerly AOP Orphan Pharmaceuticals) is a privately held Austrian company focused on rare diseases and intensive care medicine. In cancer it licensed ropeginterferon alfa-2b from PharmaEssentia for Europe and other territories, obtained European approval for polycythaemia vera in 2019 under the name Besremi, and sponsors phase 3 trials of the drug in myeloproliferative neoplasms. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Vienna, AT
Scorecard
All companies#217of 1245 companies, score 24
- approved products +6
- targets +2
- modalities +2
- regions +4
- registry trials +10
1 approved, 0 in phase 3, 0 earlier, 1 targets, 23 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
Products
1ApprovedLong-acting mono-pegylated interferon alfa
Ropeginterferon alfa-2b · Besremi
Ropeginterferon alfa-2b is a long-acting interferon for polycythaemia vera that, unlike hydroxyurea, can shrink the mutant clone over years.
Connected
4Similar pages
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals
- CompanyCyclacel Pharmaceuticals
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
aop-health.com · 1
ClinicalTrials.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/